PURPOSE: BRAFV600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAFV600E by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. METHODS: One hundred six patients with BRAFV600E-mutated metastatic CRC previously treated with one or two regimens were randomly assigned to irinotecan and cetuximab with or without vemurafenib (960 mg PO twice daily). RESULTS: Progression-free survival, the primary end point, was improved with the addition of vemurafenib (hazard ratio, 0.50, P = .001). The response rate was 17% versus 4% (P = .05), with a disease control rate of 65% versus 21% (P < .001). A decline in circulating tumor DNA BRAFV600E variant allele frequency was seen in 87% versus 0% of patients (P < .001), with a low incidence of acquired RAS alterations at the time of progression. RNA profiling suggested that treatment benefit did not depend on previously established BRAF subgroups or the consensus molecular subtype. CONCLUSION: Simultaneous inhibition of EGFR and BRAF combined with irinotecan is effective in BRAFV600E-mutated CRC.
PURPOSE: BRAFV600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAFV600E by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. METHODS: One hundred six patients with BRAFV600E-mutated metastatic CRC previously treated with one or two regimens were randomly assigned to irinotecan and cetuximab with or without vemurafenib (960 mg PO twice daily). RESULTS: Progression-free survival, the primary end point, was improved with the addition of vemurafenib (hazard ratio, 0.50, P = .001). The response rate was 17% versus 4% (P = .05), with a disease control rate of 65% versus 21% (P < .001). A decline in circulating tumor DNA BRAFV600E variant allele frequency was seen in 87% versus 0% of patients (P < .001), with a low incidence of acquired RAS alterations at the time of progression. RNA profiling suggested that treatment benefit did not depend on previously established BRAF subgroups or the consensus molecular subtype. CONCLUSION: Simultaneous inhibition of EGFR and BRAF combined with irinotecan is effective in BRAFV600E-mutated CRC.
Authors: David Barras; Edoardo Missiaglia; Pratyaksha Wirapati; Oliver M Sieber; Robert N Jorissen; Chris Love; Peter L Molloy; Ian T Jones; Stephen McLaughlin; Peter Gibbs; Justin Guinney; Iris M Simon; Arnaud D Roth; Fred T Bosman; Sabine Tejpar; Mauro Delorenzi Journal: Clin Cancer Res Date: 2016-06-27 Impact factor: 12.531
Authors: Van Morris; Michael J Overman; Zhi-Qin Jiang; Christopher Garrett; Shweta Agarwal; Cathy Eng; Bryan Kee; David Fogelman; Arvind Dasari; Robert Wolff; Dipen Maru; Scott Kopetz Journal: Clin Colorectal Cancer Date: 2014-06-23 Impact factor: 4.481
Authors: Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman Journal: Cancer Discov Date: 2012-01-16 Impact factor: 39.397
Authors: Hong Yang; Brian Higgins; Kenneth Kolinsky; Kathryn Packman; William D Bradley; Richard J Lee; Kathleen Schostack; Mary Ellen Simcox; Scott Kopetz; David Heimbrook; Brian Lestini; Gideon Bollag; Fei Su Journal: Cancer Res Date: 2011-12-16 Impact factor: 12.701
Authors: Yibing Yan; Matthew J Wongchenko; Caroline Robert; James Larkin; Paolo A Ascierto; Brigitte Dréno; Michele Maio; Claus Garbe; Paul B Chapman; Jeffrey A Sosman; Zhen Shi; Hartmut Koeppen; Jessie J Hsu; Ilsung Chang; Ivor Caro; Isabelle Rooney; Grant A McArthur; Antoni Ribas Journal: Clin Cancer Res Date: 2019-03-01 Impact factor: 12.531
Authors: David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga Journal: N Engl J Med Date: 2015-08-20 Impact factor: 91.245
Authors: Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky Journal: Nat Biotechnol Date: 2013-10-20 Impact factor: 54.908
Authors: Gary Middleton; Yiqun Yang; Catarina D Campbell; Thierry André; Chloe E Atreya; Jan H M Schellens; Takayuki Yoshino; Johanna C Bendell; Antoine Hollebecque; Autumn J McRee; Salvatore Siena; Michael S Gordon; Josep Tabernero; Rona Yaeger; Peter J O'Dwyer; Filip De Vos; Eric Van Cutsem; John M Millholland; Jan C Brase; Fatima Rangwala; Eduard Gasal; Ryan B Corcoran Journal: Clin Cancer Res Date: 2020-02-11 Impact factor: 12.531
Authors: Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Eric Van Cutsem; Sanne Huijberts; Axel Grothey; Rona Yaeger; Pieter-Jan Cuyle; Elena Elez; Marwan Fakih; Clara Montagut; Marc Peeters; Takayuki Yoshino; Harpreet Wasan; Jayesh Desai; Fortunato Ciardiello; Ashwin Gollerkeri; Janna Christy-Bittel; Kati Maharry; Victor Sandor; Jan H M Schellens; Scott Kopetz; Josep Tabernero Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: A Boccaccino; B Borelli; R Intini; M Antista; M Bensi; D Rossini; A Passardi; S Tamberi; R Giampieri; L Antonuzzo; L Noto; G Roviello; C Zichi; M Salati; A Puccini; C Noto; A Parisi; K Rihawi; M Persano; V Crespi; M Libertini; M Giordano; R Moretto; S Lonardi; C Cremolini Journal: ESMO Open Date: 2022-06-10
Authors: Chan Shen; Daniel Tannenbaum; Robert Horn; Jane Rogers; Cathy Eng; Shouhao Zhou; Benny Johnson; Scott Kopetz; Van Morris; Michael Overman; Christine Parseghian; George J Chang; Maria A Lopez-Olivo; Raghav Kanwal; Lee M Ellis; Arvind Dasari Journal: JAMA Netw Open Date: 2022-05-02
Authors: Christos Adamopoulos; Tamer A Ahmed; Maxwell R Tucker; Peter M U Ung; Min Xiao; Zoi Karoulia; Angelo Amabile; Xuewei Wu; Stuart A Aaronson; Celina Ang; Vito W Rebecca; Brian D Brown; Avner Schlessinger; Meenhard Herlyn; Qi Wang; David E Shaw; Poulikos I Poulikakos Journal: Cancer Discov Date: 2021-02-10 Impact factor: 39.397
Authors: Samuel A Jacobs; James J Lee; Thomas J George; James L Wade; Philip J Stella; Ding Wang; Ashwin R Sama; Fanny Piette; Katherine L Pogue-Geile; Rim S Kim; Patrick G Gavin; Corey Lipchik; Huichen Feng; Ying Wang; Melanie Finnigan; Brian F Kiesel; Jan H Beumer; Norman Wolmark; Peter C Lucas; Carmen J Allegra; Ashok Srinivasan Journal: Clin Cancer Res Date: 2020-11-17 Impact factor: 12.531